OCT-461201 by Oxford Cannabinoid Technologies for Neuropathic Pain (Neuralgia): Likelihood of Approval

OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Neuropathic Pain (Neuralgia).

Jun 18, 2024 - 04:00

OCT-461201 is under clinical development by Oxford Cannabinoid Technologies and currently in Phase I for Neuropathic Pain (Neuralgia).

Read the original article

Tags:

Previous Article

OCT-461201 by Oxford Cannabinoid Technologies for Visceral Pain: Likelihood of A...

MEDI-0618 by AstraZeneca for Migraine: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

Janssen’s BALVERSA receives EC approval for metastatic urothelial carcinoma

Janssen’s BALVERSA receives EC approval for metastatic ...

Aug 27, 2024

Biohaven licenses Hangzhou Highlightll’s BHV-8000 to treat brain disorders

Biohaven licenses Hangzhou Highlightll’s BHV-8000 to tr...

Mar 23, 2023

STAT+: Biotech investors push to extend time before pills are subject to price negotiations

STAT+: Biotech investors push to extend time before pil...

Oct 18, 2023